References

epidemiology

Эпидемиология и Вакцинопрофилактика

Epidemiology and Vaccinal Prevention

2073-30462619-0494

«Numicom» LLC

10.31631/2073-3046-2016-15-4-64-73

epidemiology-184

Research Article

ВАКЦИНОПРОФИЛАКТИКА

VACCINAL PREVENTION

Современные менингококковые вакцины: сильные и слабые стороны, ближайшие перпективы

Current Meningococcal Vaccines: Advantages and Disadvantages and New Challenges

Костюкова

Н. Н.

Kostyukova

N. N.

nathakos@mail.ru

Бехало

В. А.

Bekhalo

V. A.

bekhalo@gamaleya.org

ФГБУ «Федеральный научно-исследовательский центр эпидемиологии и микробиологии им. Н.Ф. Гамалеи» Минздрава РоссииRussian Federation

2016

20082016

1546473

2016

Костюкова Н.Н., Бехало В.А.

Kostyukova N.N., Bekhalo V.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.epidemvac.ru/jour/article/view/184

В обзоре рассмотрены менингококковые вакцины, как широко применяющиеся с 70-х - 80-х годов прошлого столетия, так и недавно созданные, эффективность которых еще не вполне ясна. Обсуждены достоинства и недостатки полисахаридных и гликопротеиновых вакцин против менингококков серогрупп А,С, Y,W-135, а также белковых вакцин против серогруппы В - пузырьковых и генно-инженерных, созданных на основе обратной вакцинологии. Описываются возможные варианты состава будущих вакцин. Коротко представлены данные о применении менингококковых вакцин в России. Среди ближайших задач наиболее значимыми является изучение длительности и напряженности защиты после иммунизации конъюгированными вакцинами, создание и испытание вакцины против серогруппы Х, дальнейшее изучение и совершенствование вакцин против серогруппы В, а также разработка единого препарата, защищающего от всех антигенных вариантов Neisseria meningitidis.

The article reviews and analyses the vaccines against invasive meningococcal disease, widely used in practice since 70s-80s of the last century, as well as newly developed ones, the efficacy of which is not completely clear yet. The advantages and disadvantages of polysaccharide and glycoprotein vaccines against meningococci of serogroups A, C, Y, W135 and of protein «vesicle» and geneticengineering vaccines based on «reverse vaccinology» against serogroup B are discussed. Some options for composition of future vaccines under development are presented. Briefly the meningococcal vaccines used in Russia are described. Among the most important immediate tasks discussed are: the study of the duration and intensity of protection after immunization with conjugate vaccines; the development and subsequent trials of a vaccine against serogroup X; further study and improvement of vaccines against serogroup B, as well as the creation of a single vaccine product that protects against all antigenic variants of Neisseria meningitidis.

менингококковые вакциныполисахаридные вакциныконъюгированные вакциныгенно-инженерные вакциныобратная вакцинологияthe meningococcal vaccinesthe polysaccharide vaccinesthe conjugated vaccinesthe vesicle vaccinesthe geneticengineering vaccinesreverse vaccinology

References1

Goldschneider J., Gotschlich E.C., Artenstein M.S. Human immunity to meningococcus. I. The role of humoral antibodies. J. Exp. Med. 1969; 129: 1307 -1326.

Goldschneider J., Gotschlich E.C., Artenstein M.S. Human immunity to meningococcus. I. The role of humoral antibodies. J. Exp. Med. 1969; 129: 1307 – 1326.

Gotschlich E.C., Liu T.Y., Artenstein M.S. Human immunity to meningococcus. III. Preparation and immunological properties of the groupA, group B and group C meningococcal polysaccharides. J. Exp. Med. 1969; 120: 1349 - 1365.

Artenstein M.S., Gold R., Zimmerly J.G., Whyle F.A., Schneider Y., Harkins Ch. Prevention of meningococcal disease by group C polysaccharide. N. Engl. J. Med. 1979; 272: 417 - 420.

Artenstein M.S., Gold R., Zimmerly J.G., Whyle F.A., Schneider Y., Harkins Ch. Prevention of meningococcal disease by group C polysaccharide. N. Engl. J. Med. 1979; 272: 417 – 420.

Fierbig T., Bertri F., Freiberger F., Pinto V., Claus H., Romano M.R., Proietti D., Brogioni B., Stummeyer K., Berger M. et al. Functional expression of the capsule polymerase of Neisseria meningitidis serogroup X: a new perspective for vaccine development. Glycobiology. 2014; 24 (2): 150 - 158.

Nadel S. Prospects for eradication of meningococcal disease. Arch. Dis. Child. 2012;97: 993 - 998.

Nadel S. Prospects for eradication of meningococcal disease. Arch. Dis. Child. 2012;97: 993 – 998.

Stein M.D., Robbins J. Miller M.A. Are the antibodies to the capsular polysaccharide of Neisseria meningitidis group B and Escherichia coli K1 associated with immunopathology? Vaccine. 2006; 24: 221 - 228.

Lapessonie L. Sur la vaccination antimeningococcique. Med. Trop. 1977; 37: 203 - 213.

Lapessonie L. Sur la vaccination antimeningococcique. Med. Trop. 1977; 37: 203 – 213.

Peltola H. Group A meningococcal polysaccharide vaccination and course of group A meningococcal epidemic in Finland. Scand. J. Infect. Dis. 1978; 10. Iss.1: 41 - 44

Peltola H. Group A meningococcal polysaccharide vaccination and course of group A meningococcal epidemic in Finland. Scand. J. Infect. Dis. 1978; 10. Iss.1.: 41 – 44

Harrison L.H. Epidemiological profile of meningococcal disease in the United States. Clin. Infect. Dis. 2010; 50 (52): S37 - S44.

Harrison L.H. Epidemiological profile of meningococcal disease in the United States. Clin. Infect. Dis. 2010; 50 (52): S37 – S44.

Bilucha O.O., Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practice (ACIP). MMWR Recommen. Rep. 2005; 54: 1 - 21

Bilucha O.O., Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practice (ACIP). MMWR Recommen. Rep. 2005; 54: 1 – 21.

Колесников А.В., Козырь А.В., Шемякин И.Г., Дятлов И.А. Современные представления о механизме активации иммунного ответа конъюгированными полисахаридными вакцинами. Журн. Микробиол. 2015; 3: 97 - 106.

Kolesnikov A.V., Kozyr’ A.V., Shemyakin I.G., Dyatlov I.A. Modern views on the mechanism of activation of the immune response conjugated polysaccharide vaccines. Zhurnal Mikrobiologii. [Zh. Microbiology]. 2015; 3: 97 – 106.

Stephens D.S. Protecting the herd: the remarkable effectiveness of bacterial meningitis polysaccharide-protein conjugate vaccines. Transactions of the American clinical and climatological association. 2011; 122: 115 - 123.

Ishola D.A., Borrow R., Findlow H., Findlow J., Trotter C.L., Ramsay M. Prevalenct of serum bactericidal antibodies to serogroup C Neisseria meningitidis in England a Decade after vaccine introduction. Clin. Vaccine Immunol. 2012;19 (8): 1126 - 1130.

Trotter C.L., Ramsay M.E. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccine. FEMS Microbiol. Rev. 2007; 31: 101 - 107.

Trotter C.L., Ramsay M.E. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccine. FEMS Microbiol. Rev. 2007; 31: 101 – 107.

Maiden M.C.J. The endgame for serogroup A meningococcal disease in Africa? Clin. Infect. Dis. 2013; 46 (3): 364 - 366.

Maiden M.C.J. The endgame for serogroup A meningococcal disease in Africa? Clin. Infect. Dis. 2013; 46 (3): 364 – 366.

Cardoso C.W., Ribeiro G.S., Reis M.G., Flannery B., Reis J.M. Effectiveness of meningococcal conjugate vaccine in Salvador, Brazil: a case-control study. PLOS one. 2015; 10. Iss. 4: e0123734.

Frota A.C,C., Milagres L.G., Harrison L.M., Ferreira B., Barroto D.M., Pereira G.S., Cruz A.C., Pereiro-Manfro W., de Oliveiro R.H., Abren T. et al. Immunogenicity and safety of meningococcal conjugate vaccine in children and adolescents infected and uninfected with HIV in Rio de Janeiro, Brazil. Pediatric Infect. Dis. J. 2015; 34. N 5. E 113-118.

Gasparini R., Pannato D., Bragazzi N.L, Lai P.L., Bechini A., Levi M., Durando P, Amicizia D. How the knowledges of interaction between the meningococcus and human immune system has been used to prepare effective Neisseria meningitis vaccine. Hindawi Publ. Corp. J. Immunol. Res. 2015. V. 2015/Article ID 189153. http/dx.doi.org/10.1155/2015/189153/

Gasparini R., Pannato D., Bragazzi N.L, Lai P.L., Bechini A., Levi M., Durando P., Amicizia D. How the knowledges of interaction between the meningococcus and human immune system has been used to prepare effective Neisseria meningitis vaccine. Hindawi Publ. Corp. J. Immunol. Res. 2015. V. 2015/Article ID 189153. http/dx.doi.org/10.1155/2015/189153/

Broderick M.P., Phillips Ch., Faix D. Meningococcal disease in US military personnel before and after adoption of conjugate vaccines. Emerg. Infect. Dis. 2015; 21; 2: 377 - 379.

Broderick M.P., Phillips Ch., Faix D. Meningococcal disease in US military personnel before and after adoption of conjugate vaccines. Emerg. Infect. Dis. 2015; 21; 2: 377 – 379.

Meningococcal vaccines: WHO position paper. Weekley epid. record. 2011; 86 (47): 521 - 540.

Meningococcal vaccines: WHO position paper. Weekley epid. record. 2011; 86 (47): 521 – 540.

Borrow R. Advances with vaccination against Neisseria meningitidis. Trop. Med. International. 2012; 17 (12): 1478 - 1491.

Borrow R. Advances with vaccination against Neisseria meningitidis. Trop. Med. International. 2012; 17 (12): 1478 – 1491.

Novak R.T., Kambou J.L., Dimand F.V., TarbangdoT.F., Qu drago-Traore R., Sangar L., Lingani C., Martin S.W., Hatcher S., Mayer L.W. et al. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet. Infect. Dis. 2012; 12: 354 - 363.

Novak R.T., Kambou J.L., Dimandé F.V., TarbangdoT.F., Quédrago-Traore R., Sangaré L., Lingani C., Martin S.W., Hatcher S., Mayer L.W. et al. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet. Infect. Dis. 2012; 12: 354 – 363.

Kristiansen PA., Diomand T., Tarbangdo T.F., Ku Ba A., Qu draogo A.-S., Qu draogo R., Sangar L.,Kandolo D., Ak F.,Saga G.M., et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin. Infect. Dis. 2013; 56: 354 - 363.

Kristiansen P.A., Diomandé T., Tarbangdo T.F., Ku Ba A., Quédraogo A.-S., Quédraogo R., Sangaré L.,Kandolo D., Aké F.,Saga G.M., et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin. Infect. Dis. 2013; 56: 354 – 363.

Фаворова Л.А., Телешевская Э.Я. Эпидемиология и профилактика менингококковой инфекции. Сов. Медицина. 1971; 11: 113 - 118.

Favorova L.E., Teleshevskaya E.Ya. Epidemiology and prevention of meningococcal disease. Sovetskaya medecina. [Soviet medicine]. 1971; 11: 113 – 118.

Kulkarni H.M., Jagannadham M.V. Biogenesis and multifaceted roles of outer membrane vesicles from Gram-negative bacteria. Microbiology. 2014; 160: 2109 - 2121.

Kulkarni H.M., Jagannadham M.V. Biogenesis and multifaceted roles of outer membrane vesicles from Gram-negative bacteria. Microbiology. 2014; 160: 2109 – 2121.

Sierra G.V., Campa N.C., Varcacel N.M., Garcia I.L., Isquierdo P.L., Sotolongo PF., Gazanueva G.V., Rico C.O., Rodriges C.R., Ferry M.H. Vaccine against group B Neisseria meningitidis: protection trail and mass vaccination results in Cuba. NIPH Ann. 1991; 14: 195 - 210.

Sierra G.V., Campa N.C., Varcacel N.M., Garcia I.L., Isquierdo P.L., Sotolongo P.F., Gazanueva G.V., Rico C.O., Rodriges C.R., Ferry M.H. Vaccine against group B Neisseria meningitidis: protection trail and mass vaccination results in Cuba. NIPH Ann. 1991; 14: 195 – 210.

Galloway Y., Stehr-Green P, McNicolas A., O Hallahan J. Use and observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int. J. Epid. 2009; 38: 413 - 418.

Galloway Y., Stehr-Green P., McNicolas A., O´Hallahan J. Use and observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int. J. Epid. 2009; 38: 413 – 418.

Thomas M. Prevention of group B meningococcal disease by vaccination: a difficult task. J. New Zealand Med. Ass. 2004; 117 (1200).

Devoy A.F., Dyet K.N., Martin D.R. Stability of Por A during a meningococcal disease epidemic. J. Clin. Microbiol. 2005; 43 (2): 832 - 837.

Devoy A.F., Dyet K.N., Martin D.R. Stability of Por A during a meningococcal disease epidemic. J. Clin. Microbiol. 2005; 43 (2): 832 – 837.

Rappuoli R. Reverse vaccinology. Curent Opinion in Microbiology. 2000; 3: 445 - 450.

Rappuoli R. Reverse vaccinology. Curent Opinion in Microbiology. 2000; 3: 445 – 450.

Pizza M., Scarlato V., Masignani V., Frico B., Comanducci M., Jenings G.T., Giolani M.M., Baldi L., Bacdini E., Capeci B. et al. Identification of vaccine candidate against serogroup B meningococci by whole-genome sequesing. Science. 2000; 287 (5459): 1816 - 1820.

Comanducci V., Bambini S., Caugant D., Mora M., Brunelli B.,Capecci B., Chiucci L., Rappuoli R., Pizza M. Nad A diversity and carriage in Neisseria meningitidis. Infect. Immun. 2004; 72 (7): 4217 - 4223.

Tan L.K.K., Carlone G.M., Borrow R. Advances in the development of vaccines against Neisseria meningitidis. New Engl. J. Med. 2010; 362 (16): 1511 - 1520.

Tan L.K.K., Carlone G.M., Borrow R. Advances in the development of vaccines against Neisseria meningitidis. New Engl. J. Med. 2010; 362 (16): 1511 – 1520.

Schneider M.S., Prosser B.E., Caesar J.J., Kugelsberg E., Zhang Q., Quoraishi S., Lovett J.E., Deane J.E., Sim R.B., Rodersi P. et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature. 2009; 458: 890 - 893.

Платонов А.Е, Харит С.М., Платонова О.В. Вакцинопрофилактика менингококковой инфекции в мире и в России. Эпидемиология и Вакцинопрофилактика. 2009; 5: 32 - 46.

Platonov A.E., Harith S.M., Platonova OV. Vaccination of meningococcal disease in the world and in Russia. Epidemiologya and Vaccinoprofilaktika. [Epidemiology & Vaccinal Prevention]. 2009; 5: 32 – 46.

Granoff D.M., Welsch J.A., Ram S. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect. Immun. 2009; 27 (2): 764 - 769.

Madico G., Welsch J.A., Lewis L.A., McNaughton A., Perlman D.N., Costello C.E., Ngampasutadol J., Vogel U., Granoff D.M., Ram S. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol. 2006; 177: 501 - 510.

Harris S.L., Zhu D., Murphy E., McNeil L.K., Wang X., Mager L.W., Harrison L.H., Jansen K.U. Anderson A.S. Principal evidence for the potential of a bivalent fHbp vaccine to protect from Neisseria meningitidis serogroup C. Human Vaccines. 2011; 7. Suppl. 1: 68 - 74.

Serruto D., Spadafina T., Ciucci L., Lewis L.A., Ram S., Tontini M., Santini L., Biolchi A., Seib K.L., Giulliani M.M. et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. PNAS. 2010; 107 (8): 3770 - 3775.

Serruto D., Spadafina T., Ciucci L., Lewis L.A., Ram S., Tontini M., Santini L., Biolchi A., Seib K..L., Giulliani M.M. et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. PNAS. 2010; 107 (8): 3770 – 3775.

Bambini S., Piet J., Muzzi A., Keijzers W., Comandi S. De Tora L., Pizza M., Rappuoli R., van de Beek D., van der Ende A., Comanduccci M. An analysis of the sequence variability of meningococcal fHbp, NadA and NHBA over 50-year period in the Netherlands. PloS one. 2013; 8. Iss. 5. e 65043

Bambini S., Piet J., Muzzi A., Keijzers W., Comandi S.. De Tora L., Pizza M., Rappuoli R., van de Beek D., van der Ende A., Comanduccci M. An analysis of the sequence variability of meningococcal fHbp, NadA and NHBA over 50-year period in the Netherlands. PloS one. 2013; 8. Iss. 5. e 65043

McIntosh E.X., Carey V., Toneatto D., Dull P., James W. Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals - the example of serogroup B meningococcal infection. Ther. Adv. Vaccines. 2015; 3 (1): 13 - 23.

McIntosh E.X., Carey V., Toneatto D., Dull P., James W. Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals – the example of serogroup B meningococcal infection. Ther. Adv. Vaccines. 2015; 3 (1): 13 – 23.

Richmond PC., Marshal H.S., Nissen M.A., Jiang Q., Jansen K.U., Garcies-Sanches M., Martinon-Torres F., Boeslar J., Szeszek L., Wisocki J. et al., on behalf of 2001 study Investigators. Safety, immunogenicity and tolerability of meningococcus serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised single-blind, placebo-controlled phase 2 trial. Lancet Infect. Dis. 2012; 12 (8): 97 - 6074.

Richmond P.C., Marshal H.S., Nissen M.A., Jiang Q., Jansen K.U., Garcies-Sanches M., Martinon-Torres F., Boeslar J., Szeszek L., Wisocki J. et al., on behalf of 2001 study Investigators. Safety, immunogenicity and tolerability of meningococcus serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised single-blind, placebo-controlled phase 2 trial. Lancet Infect. Dis. 2012; 12 (8): 97 – 6074.

Follarmini T., Rubin L., Martin S.W., Patel M., MacNeil J.R. Use of serogroup B meningococcal vaccines in persons aged >10 years at increased risk for serogroup B meningococcal disease: recommendatons of the Divisory Committee of immunization practice. MMMR. 2015; 64 (22): 608 - 612.

Follarmini T., Rubin L., Martin S.W., Patel M., MacNeil J.R. Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: recommendatons of the Divisory Committee of immunization practice. MMMR. 2015; 64 (22): 608 – 612.

Kristiansen PA., Ku Ba A., Sanon I., Qu draogo A.S., Qu draogo R.,Sangar L., Diomand F.,Kandolo D.,Thomas J.D., Clark Th.A. et al. Phenotyping and genotyping characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup A conjugate vaccine. BMC Infect. Dis. 2013; 13: 363 - 373.

Kristiansen P.A., Ku Ba A., Sanon I., Quédraogo A.S., Quédraogo R.,Sangaré L., Diomandé F.,Kandolo D.,Thomas J.D., Clark Th.A. et al. Phenotyping and genotyping characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup A conjugate vaccine. BMC Infect. Dis. 2013; 13: 363 – 373.

Swartley J.S., Martin A.A., Edupugantii S., Liu L.J., Cieslak P., Perkins B., Wenger J.D., Stephens D.S. Capsule switching of Neisseria meningitidis. Proc. Natl. Acad. Sci. USA. 1997; 94: 271 - 276.

Swartley J.S., Martin A.A., Edupugantii S., Liu L.J., Cieslak P., Perkins B., Wenger J.D., Stephens D.S. Capsule switching of Neisseria meningitidis. Proc. Natl. Acad. Sci. USA. 1997; 94: 271 – 276.

Stephanelli P., Fazio C., Neri A., Sofia T., Mastrantonio Fi First report of capsule replacement among electrophoretic type strains in Italy. J. Clin. Microbiol. 2003; 4 (12): 5783 - 5786.

Stephanelli P., Fazio C., Neri A., Sofia T., Mastrantonio P. First report of capsule replacement among electrophoretic type strains in Italy. J. Clin. Microbiol. 2003; 4 (12): 5783 – 5786.

Harrison L.H., Schutt R.A., Schmink S.E., Marsch J.W., Harcoart B.H., Wang X., Whitney A.M., Stephens D.S., Cohn A., Messionnier N.E., Mayer L.W. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era - United States, 2000-2005. J. Infect. Dis. 2010; 201: 1208 - 1224.

Wang Q., Shao Z., Wang X., Gao Y., Li M., Xu J., Wang L. Genetic study of capsular switching between Neisseria meningitidis seequence type 7 serogroupA and C strains. Infect. Immun. 2010; 78 (9): 3883 - 3888.

Alcala B., Arreaza L., Salcedo C., Uria M.J., De La Fuente L., V zques L.A. Capsule switching among C:2b:P1.2,5 meningococcal epidemic strains after mass immunization campaign, Spain. Emerg. Infect. Dis. 2002; V.8: 1512 - 1514.

Alcala B., Arreaza L., Salcedo C., Uria M.J., De La Fuente L., Vázques L.A. Capsule switching among C:2b:P1.2,5 meningococcal epidemic strains after mass immunization campaign, Spain. Emerg. Infect. Dis. 2002; V.8: 1512 – 1514.

Ibarz-Pav n A.B., MacLennan J., Andrews N.J., Gray S., Urwin R., Clarc S.C., Walker A.M., Evans M.R., Kroll J.S., Neal K.R. et al. Changes in serogroup and genotype prevalence among carried meningococci in the United Kingdom during vaccine implementation. J. Infect. Dis. 2011; 204: 1046 - 1053.

Ibarz-Pavón A.B., MacLennan J., Andrews N.J., Gray S., Urwin R., Clarc S.C., Walker A.M., Evans M.R., Kroll J.S., Neal K.R. et al. Changes in serogroup and genotype prevalence among carried meningococci in the United Kingdom during vaccine implementation. J. Infect. Dis. 2011; 204: 1046 – 1053.

Vincente D., Esnal O., de Goicoechia J.L., Cisterna R., P rez-Trallero E. Influence of two vaccination campaigns on genetic diversity of invasive Neisseria meningitidis isolates in Nothern Spain (1997 - 2008). PloS one. 2009; 4. Iss. 12. e8501

Vincente D., Esnal O., de Goicoechia J.L., Cisterna R., Pérez-Trallero E. Influence of two vaccination campaigns on genetic diversity of invasive Neisseria meningitidis isolates in Nothern Spain (1997 – 2008). PloS one. 2009; 4. Iss. 12. e8501

Block S.L., Szenborn L., Daly N., Jackowska T., D Agastorn D., Han L., et al. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: results of a phase 2 randomized controlled trial. Vaccine. 2015; 33 (21): 2500 - 2510.

Block S.L., Szenborn L., Daly N., Jackowska T., D′Agastorn D., Han L., et al. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: results of a phase 2 randomized controlled trial. Vaccine. 2015; 33 (21): 2500 – 2510.

Weynants V., Deho l P., Devos N., Janssens D., Feron C., Goraj K., Momin P, Monnom D., Tans C., Vandercammen A. et al. Genetically modified L3,7 and L2 lipoolygosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response. Infect. Immun. 2009; 87: 2084 - 2093.

Weynants V., Dehoël P., Devos N., Janssens D., Feron C., Goraj K., Momin P., Monnom D., Tans C., Vandercammen A. et al. Genetically modified L3,7 and L2 lipoolygosaccharides from Neisseria meningitidis serogroup B confer a broad cross- bactericidal response. Infect. Immun. 2009; 87: 2084 – 2093.

Hung M.-C., Heckels J.E., Christodoulides M. Adhesin complex protein (ACP) of Neisseria meningitidis is a new adhesin with vaccine potential. mBIO. 2013; 4; Iss. 2. e00041-13

Peak J.R., Srikhanta J.N., Weynants V.E., Feron Ch., Poolman J.V. Jennings M.N. Evaluation of truncated NhhA protein as a candidate meningicoccal vaccine antigen. PloS one. 2013; V.8; Iss. 9. e72003

Lewis L.A., Ngampasutadol J., Wallace R., Reid J.E.A., Vogel U., Ram S. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PloS pathogens. 2010; 6; Iss. 7. e10001027

Halperin S.A., Langley J.M., Smith B., Wunderli P., Kaufman L., Kimura A., Martin D. Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine. 2007; 25: 450 - 475.

Li Y., Sun Y.-H., Ison C., Levine M., Tang Ch.M. Vaccination with attenuated Neisseria meningitidis strains protects against challenge with live meningococcci. Infect. Immun. 2004; 72 (1): 345 - 350.

Li Y., Sun Y.-H., Ison C., Levine M., Tang Ch.M. Vaccination with attenuated Neisseria meningitidis strains protects against challenge with live meningococcci. Infect. Immun. 2004; 72 (1): 345 – 350.

Bennet J.S., Calligan M.J., Derrich J.P., Maiden M.C.J. Variation of the Neisseria lactamica porin and its relationship to meningococcal PorB. Microbiology. 2008; 154: 1525 - 1534.

Bennet J.S., Calligan M.J., Derrich J.P., Maiden M.C.J. Variation of the Neisseria lactamica porin and its relationship to meningococcal PorB. Microbiology. 2008; 154: 1525 – 1534.

Evans C.M., Prett C.B., Matheson M., Vaughan T.E., Findlow J., Borrow R., Gorringe A.R., Read R.C. Nasopharyngeal colonization by Neisseria lactamica and induction of protective immunity against Neisseria meningitidis. Clin. Infect. Dis. 2011; 52 (1): 70 - 77.

Костюкова Н.Н., Бахаев Ю.П., Беломестных Е.Л., Дуплищева В.А., Кирпичникова Е.Н., Кузмин Ю.К. и др. Опыт массовой вакцинопрофилактики менингококковой инфекции среди детей. В кн.: Острые менингиты. Москва. 1982: 31 - 37

Kostyukova N.N., Bakhaev Y.P., Belomestnykh E.L., Duplischeva V.A., Kirpichnikova E.N., Kuzmin Yu.K. et al. The experience of mass vaccination of meningococcal disease among children. In: Acute meningitis. Moscow. 1982: 31 – 37.

Костюкова Н.Н., Бехало В.А., Чернышева Т.Ф. Менингококковая инфекция в России - прошлое и ближайшие перспективы. Эпидемиол. инфекц. бол. Актуальные вопросы. 2014; 2: 73 - 79.

Kostyukova N.N., Bеkhalo V.A., Chernysheva T.F. Meningococcal disease in Russia - the past and the near-term prospects. Epidemiologya i infekcionnije bolezni. Aktualnie voprosi. [Epidemiology of infectious. diseases. Topical issues]. 2014; 2: 73 – 79.

Королева И.С., Белошицкий Г.В., Королева М.А., Закроева И.М., Спирихина Л.В., Миронов К.О., Шипулин Г.А. Менингококковая инфекция и гнойные бактериальные менингиты в Российской Федерации: десятилетнее эпидемиологическое наблюдение. Эпидемиол. инфекц. бол. Актуальные вопросы. 2013; 2: 14 - 20.

Koroleva I.S., Beloshitsky G.V., Koroleva M.A., Zakroeva I.M., Spirikhina L.V., Mironov K.O., Shipulin G.A. Meningococcal infection and purulent bacterial meningitis in the Russian Federation: a ten-year epidemiological surveillance. Epidemiologya i infekcionnije bolezni. Aktualnie voprosi. [Epidemiology. infection. bol. Topical issues]. 2013; 2: 14 – 20.

Санитарно-эпидемиологические правила СП.3.1.2.2512-09. Профилактика менингококковой инфекции.

Sanitary rules SR. 3.1.2.2512-09. Prevention of meningococcal disease.

Приказ Министерства здравоохранения от 21 марта 2014 г. № 125н: Об утверждении национального календаря прививок и профилактических прививок по эпидемиологическим показаниям.

Order of the Ministry of Healthcare on 21 March 2014. № 125n: On approval of the national calendar of vaccinations and prophylactic vaccinations for epidemiological indications.

The authors declare that there are no conflicts of interest present.